thalidomide has been researched along with Elevated Cholesterol in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with Thalidomide preserved VV spatial density [2." | 1.35 | Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. ( Galili, O; Gössl, M; Herrmann, J; Lerman, A; Lerman, LO; Mannheim, D; Rajkumar, SV; Tang, H; Versari, D, 2009) |
| "Attenuated inflammation and pathological angiogenesis achieved in hypercholesterolemia by thalidomide are accompanied by restoration of renovascular endothelial function but decreased basal renal hemodynamics." | 1.34 | Role of renal cortical neovascularization in experimental hypercholesterolemia. ( Chade, AR; Galili, O; Krier, JD; Lerman, A; Lerman, LO, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fumian, MM | 1 |
| da Motta, NA | 1 |
| Maia, R | 1 |
| Fraga, CA | 1 |
| Barreiro, EJ | 1 |
| Ferreira de Brito, FC | 1 |
| Gössl, M | 1 |
| Herrmann, J | 1 |
| Tang, H | 1 |
| Versari, D | 1 |
| Galili, O | 2 |
| Mannheim, D | 1 |
| Rajkumar, SV | 1 |
| Lerman, LO | 2 |
| Lerman, A | 2 |
| Shahan, JL | 1 |
| Panu, LD | 1 |
| Hildebrandt, GC | 1 |
| Chade, AR | 1 |
| Krier, JD | 1 |
4 other studies available for thalidomide and Elevated Cholesterol
| Article | Year |
|---|---|
LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition of TNF-α production.
Topics: Animals; Cholesterol, HDL; Dose-Response Relationship, Drug; Hypercholesterolemia; Male; Rats; Rats, | 2016 |
Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia.
Topics: Actins; Angiogenesis Inhibitors; Animals; Blotting, Western; Chemokine CXCL1; Coronary Vessels; Dise | 2009 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combi | 2012 |
Role of renal cortical neovascularization in experimental hypercholesterolemia.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Blood Pressure; Cell Proliferation; Disease Model | 2007 |